China Resources Pharmaceutical Group (3320) H2 2024 earnings summary

Executive summary

• Revenue reached RMB 257.7 billion in 2024, up 5.3% year-over-year, with net profit at RMB 8.4 billion, up 8.1%.

• Industry position remains strong, ranking third overall in scale and leading in several segments.

• High-quality growth driven by business optimization, innovation, and digital transformation.

• Strategic focus on R&D, green low-carbon initiatives, and SOE reform.

• Basic EPS was RMB 0.53 (2023: RMB 0.61); a final dividend of RMB 0.052 per share is proposed.

Financial highlights

• Gross profit rose 6.1% to RMB 40.7 billion; gross margin stable at 15.8%.

• Net profit attributable to shareholders was RMB 3.35 billion, down 13.1% year-over-year; adjusted net profit (excluding non-recurring items) increased 13.1% to RMB 9.41 billion.

• Operating cash flow improved 12.8% to RMB 17.5 billion.

• Gearing ratio increased to 52.3% (2023: 42.2%), and current ratio improved to 1.4:1.

• Full-year dividend payout ratio at 25%.

Outlook and guidance

• Focus on management enhancement, external expansion, and digital/AI empowerment for sustained growth.

• Continued investment in innovative drugs, blood products, high-end medical devices, and synthetic biology.

• Commitment to green, low-carbon development and regional expansion in key economic zones.

• Emphasis on quality and efficiency through R&D, M&A, and regional expansion.